Objective To investigate the prevalence rate of vertebral fracture in a single transplant centre and analyze the disease risk factors. Methods Liver transplantation patients were enrolled from August 2011 to February 2013 in The General Hospital of Chinese People’s Armed Police Forces. Inclusion criteria:1.Liver transplantation for the first time; 2.Age of 20-70 years.Exclusion criteria:1.Pregnancy or lactation. 2.Other organ transplantation.The data collected from electronic medical records were as follows: demographic characteristics (age, gender, BMI), history of liver disease, immunosuppressive treatment. Frontal and lateral X-ray films of thoracolumbar spine was measured. Results 179 patients were analyzed, including 151 men and 28 women, aging from 30 to 69 years old (mean age 51.5 years).The prevalence rates of vertebral fracture was 32.4%.Prevalence of slight, medium and severe vertebral fractures were 74.1%,19.0% and 6.9%, respectively.0.5-2 years postoperatively with vertebral fracture prevalence was highest, 51.4%.Prevalence of vertebral fractures after the surgery mainly involved with glucocorticoid and calcineurin inhibitor dosage, in addition to age.After surgery, the use of diphosphonate could reduce the prevalence of vertebral fractures in patients with liver transplantation in Europe and the United States. Conclusions There are high vertebral fracture rates in patients undergoing liver transplantation. This rate is likely to reflect long-term use of glucocorticoid and immunosuppressants .It is suggested that we should, on the basis of calcium and vitamin D, select the double phosphonic acid salt to prevent and treat osteoporosis and bone fracture after liver transplantation.
Key words
liver transplantation /
vertebral fracture /
tacrolimus
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Alcalde V A, Pascasio A J M.Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation[J]. Transplant Proc, 2012,44(6):1496-1498.
[2] Fabrega E, Orive A, Garcia-Unzueta M,et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transpla- ntation[J]. Clin Transplant, 2006,20(3):383-388.
[3] Loria I, Albanese C, Giusto M,et al.Bone disorders in patients with chronic liver disease awaiting liver Transplantation[J].Transpl P,2010,42:1191- 1193.
[4] Chauhan V, Ranganna K M, Chauhan N, et al.Bone disease in organ transplant patients: pathogenesis and management[J]. Postgrad Med,2012,124(3):80-90.
[5] Kaemmerer D, Benjamin S, Gabriele L, et al.Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation[J]. Transplant Res,2012,1(1): 1440-1447.
[6] Premaor M O, Das T K, Debiram I, et al.Fracture incidence after liver transplantation: results of a 10-year audit[J].Q J Med ,2011,104 :599-606.
[7] Genant H K,Wucy,Van Kuijc,et al.Vertebral fracture assessment using semiquantitativea technique[J].J Bone Miner Res,1993,8(9):113-114.
[8] Navasa M, Monegal A, Guanabens N, et al.Bone fractures in liver transplant patients[J]. Brit J Rheumatol, 1994, 33:52-55.
[9] Ebeling P R. Approach to the patient with transplantation-related bone loss[J]. J Clin Endocrinol Metab,2009,94(5):1483-1490.
[10] Wagner D, Amrein K, Dimai H P,et al.Ibandronate and calcitriol reduces fracture risk, reverses boneloss, and normalizes bone turnover after LTX[J]. Transplantation,2012, 93(3):331-336.
[11] Crawford B A, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 2006,144(4):239-248.
[12] Pennisi P, Trombetti A, Giostra E. Pamidronate and osteoporosis prevention in liver transplant recipients[J]. Rheumatol Int, 2007,27(3):251-256.
[13] Ninkovic M,Love S A,Tom B,et al.High prevalence of osteoporosis in patient witll chronic liver disease prior to liver transplantation[J].Calcif Tissue Int,2001, 69(6):321-326.
[14] Weinstein R S.Glucocorticoid-induced bone disease[J].N Engl J Med,2011,365(1):62-70.
[15] Sun L,Peng Y,Zaidi N,et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts[J].Am J Physiol Renal Physiol,2007,292(1):285-291.
[16] Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis[J]. Endocrinol Metab Clin North Am,2007,36(4):937-963.
[17] Varanasi S S, Datta H K.Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfal and osterix in ROS 17/2.8 cells[J]. Bone, 2005,36 (2): 243-253.
[18] Fukunaga J,Yammai T,Yamachika E,et al.Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppr- essant FK506[J]. Bone, 2004,34(3): 425-431.
[19] Sun L,Blair H C,Peng Y, et al.Calcineurin regulates bone formation by the osteoblast[J]. Proc Natl Acad Sci USA, 2005. 102(47): 17130-17135.
[20] Armas L A, Recker R R.Pathophysiology of osteoporosis: new mechanistic insights[J]. Endocrinol Metab Clin North Am, 2012 ,41(3):475-86.
PDF(867 KB)
